Jiangsu Recbio Technology Co., Ltd. (02179)
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vac
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
